Eli Lilly | LLY - Operating Profit

Stock Price
1,043.57
Daily Change
6.42 0.62%
Monthly
0.20%
Yearly
28.77%
Q1 Forecast
1,005.21

Eli Lilly reported $8.39B in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Abbott USD 2.25B 73M Dec/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Amgen USD 4.43B 1.77B Sep/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
Baxter International USD 201.2M 70.8M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
GlaxoSmithKline GBP 2.79B 764M Sep/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Medtronic USD 1.7B 100M Sep/2025
Merck USD 6.55B 189M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD 4.5B 363M Sep/2025
Novartis USD 4.58B 879M Sep/2025
Novo Nordisk DKK 34.08B 4.71B Jun/2025
Perrigo USD 93.4M 37.8M Sep/2025
Pfizer USD 652M 3.67B Sep/2025
Prestige Brands USD 79.67M 7.91M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sanofi EUR 1.5B 2.29B Dec/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Zoetis USD 936M 63M Sep/2025